Orthogon Therapeutics LLC is categorized under Commercial Biotechnical Research in Hyde Park, MA and active since 2012.
Orthogon Therapeutics LLC was established in 2012, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Ali Munawar at the company’s single location by writing to 10 Kardon Road, Hyde Park, Massachusetts MA 02136 or by phoning (617) 942-2946. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Orthogon Therapeutics LLC |
Contact Person: | Ali Munawar |
Address: | 10 Kardon Road, Hyde Park, Massachusetts 02136 |
Phone Number: | (617) 942-2946 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2012 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Commercial Biotechnical Research |
SIC Code: | 8731 |
NAICS Code: | 541711 |
Share This Business: |
Orthogon Therapeutics LLC was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Ali Munawar for inquiries that concern Orthogon Therapeutics LLC by calling the company number (617) 942-2946, as your correspondence is most welcome. Additionally, the physical location of the single location of Orthogon Therapeutics LLC can be found at the coordinates 42.253297,-71.140683 as well as the street address 10 Kardon Road in Hyde Park, Massachusetts 02136.
For its online presence, you may visit Orthogon Therapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.